3-(1-carboxycyclopentyl)-2-(2-methoxyethyl)propanoic acid benzyl ester | 118786-35-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(1-carboxycyclopentyl)-2-(2-methoxyethyl)propanoic acid benzyl ester
• 英文别名: 1-(2-benzyloxycarbonyl-4-methoxybutyl)cyclopentane carboxylic acid；1-{2-[(benzyloxy)carbonyl]-4-methoxybutyl}cyclopentanecarboxylic acid；1-{2-[(Benzyloxy)carbonyl]-4-methoxybutyl}-cyclopentanecarboxylic acid；1-(4-methoxy-2-phenylmethoxycarbonylbutyl)cyclopentane-1-carboxylic acid
• CAS: 118786-35-9
• 化学式: C₁₉H₂₆O₅
• 分子量: 334.412
• InChiKey: KBXLLXNYYSFLDF-UHFFFAOYSA-N

物化性质

• 沸点：
  479.8±25.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(1-carboxycyclopentyl)-2-(2-methoxyethyl)propanoic acid benzyl ester 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、103.42 kPa 条件下， 反应 15.0h， 生成 4-Methoxy-2-[[1-(2-phenylethylcarbamoyl)cyclopentyl]methyl]butanoic acid
  参考文献：
  名称：

  Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder

  摘要：

  A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). In this paper, we describe studies in which we were able to increase NEP activity substantially over the levels reported for previous compounds from this programme by appropriate substitution in both the P'(1) and P'(2) regions. Optimisation led to the 4-chlorophenpropylamide S-30 which was selected as a candidate for further study. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.002
• 作为产物：
  描述：

  2-(2-methoxyethyl)malonic acid dibenzyl ester 在 氢氧化钾 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 水 为溶剂， 反应 23.5h， 生成 3-(1-carboxycyclopentyl)-2-(2-methoxyethyl)propanoic acid benzyl ester
  参考文献：
  名称：

  Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder

  摘要：

  A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). In this paper, we describe studies in which we were able to increase NEP activity substantially over the levels reported for previous compounds from this programme by appropriate substitution in both the P'(1) and P'(2) regions. Optimisation led to the 4-chlorophenpropylamide S-30 which was selected as a candidate for further study. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.002

文献信息

• Glutaramide diuretic agents
  申请人：Pfizer Inc.

  公开号：US05030654A1

  公开（公告）日：1991-07-09

  A series of novel spiro-substituted glutaramide derivatives have been prepared, including the pharmaceutically acceptable salts thereof and bioprecursors therefor, wherein the spiro-substituent completes a 5- or 6-membered carbocycyclic ring and is located at the carbon atom adjacent to the carbamoyl group. These particular compounds are inhibitors of the neutral endopeptidase E.C.3.4.24.11 enzyme and are therefore useful in therapy as diuretic agents for the treatment of hypertension, heart failure, renal insufficiency and other disorders. Methods for preparing these compounds from known starting materials are provided.

  已制备了一系列新颖的螺环取代谷氨酰胺衍生物，包括其药用可接受盐和生物前体，其中螺环取代基完成一个5-或6-成员碳环，并位于相邻于羰胺基团的碳原子上。这些特定化合物是中性内切肽酶E.C.3.4.24.11酶的抑制剂，因此在治疗高血压、心力衰竭、肾功能不全和其他疾病中作为利尿剂剂而有用。提供了从已知起始物质制备这些化合物的方法。
• Phosphodiesterase inhibitors for the treatment of female sexual dysfunction
  申请人：Pfizer Limited

  公开号：EP1097706A1

  公开（公告）日：2001-05-09

  A method of treating a female suffering from femal sexual dysfunction (FSD), in particular femal sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. Said agent is a phosphodiesterase (PDE) inhibitor wherein said PDE is a cAMP hydrolysing PDE (and optionally cGMP hydroysing).

  描述了一种治疗女性性功能障碍（FSD），特别是女性性唤醒功能障碍（FSAD）的方法。该方法包括向女性提供一种能够增强性生殖器内环磷酸腺苷（cAMP）的药物；其中，该药物的量足以引起女性性生殖器内cAMP的增强。该药物可以与药用可接受的载体、稀释剂或赋形剂混合。所述药物是一种磷酸二酯酶（PDE）抑制剂，其中所述PDE是一种cAMP水解PDE（可选地为cGMP水解）。
• Treatment of male sexual dysfunction
  申请人：——

  公开号：US20020028799A1

  公开（公告）日：2002-03-07

  The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.

  本发明涉及使用中性内肽酶抑制剂（NEPi）和NEPi与磷酸二酯酶5型（PDE5）抑制剂的组合物治疗男性性功能障碍，特别是MED。
• [EN] CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE<br/>[FR] DERIVES DE GLUTARAMIDE SUBSTITUES PAR DU CYCLOPENTYL UTILISES COMME INHIBITEURS DE L'ENDOPEPTIDASE NEUTRE
  申请人：PFIZER LTD

  公开号：WO2002002513A1

  公开（公告）日：2002-01-10

  The invention provides compounds of formula I wherein R1 is optionally substituted C¿1?-6alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; n is 0, 1 or 2; and Y is -NR?18S(O)¿uR19 or a group shown below.

  该发明提供了公式I的化合物，其中R1是可选取代的C1-6烷基，可选取代的C3-7环烷基，可选取代的芳基或可选取代的杂环基；n为0，1或2；Y为-NR?18S(O)uR19或下图所示的基团。
• Compounds for the treatment of female sexual dysfunction
  申请人：Pfizer Inc

  公开号：US20040254153A1

  公开（公告）日：2004-12-16

  A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.

  本发明描述了一种治疗患有女性性功能障碍（FSD），特别是女性性唤起障碍（FSAD）的方法。该方法包括向女性输送一种能够在性生殖器中增强cAMP的药剂；其中该药剂的量足以在女性的性生殖器中引起cAMP的增强。该药剂可以与药学上可接受的载体、稀释剂或赋形剂混合。